Evidence map›Paper›PMID 30410486›Full record

ArticleFrontiers in immunology2018

Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis.

Harald Hegen, Janette Walde, Gabriel Bsteh, Michael Auer, Sebastian Wurth, Anne Zinganell, Franziska Di Pauli, Florian Deisenhammer, Thomas Berger

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Improving risk-stratification of natalizumab-associated PML.Annals of clinical and translational neurology · 2021
    Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Harald HegenDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Janette WaldeDepartment of Statistics, Faculty of Economics and Statistics, University of Innsbruck, Innsbruck, Austria.
Gabriel BstehDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Michael AuerDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Sebastian WurthDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Anne ZinganellDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Franziska Di PauliDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Florian DeisenhammerDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Thomas BergerDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAntibodies, ViralBiomarkersFemaleHumansImmunosuppressive AgentsJC VirusLongitudinal StudiesMaleMiddle AgedMultiple SclerosisPolyomavirus InfectionsSeroconversionAntibodies, ViralBiomarkersImmunosuppressive Agentsanti-JCV antibody indexglatiramer acetateinterferon betaJC viruslongitudinalmultiple sclerosisnatalizumabseroconversion

Identifiers

PMID30410486
PMCPMC6209669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.